Samsung investigates Galaxy Watch 8 to mitigate muscle loss in Ozempic and GLP-1 users

Samsung began developing research to investigate the effectiveness of Galaxy Watch 8. The study seeks to help adults who have started treatments with GLP-1-based drugs, such as Ozempic, Wegovy and Mounjaro, to mitigate the loss of muscle mass during the process. Esta initiative reflects a significant advancement in the convergence between wearable technology and healthcare, focusing on a common side effect of these therapies.
Anunciada this Thursday (28), the research aims to verify whether the South Korean company’s smartwatch can monitor and help mitigate the loss of muscle mass, a challenge faced by many patients using these drugs. The collaboration with Centro of Pesquisa in Diabetes (DRC) of Hospital Geral of Massachusetts (MGH) solidifies the scientific nature of the investigation. The decision to continue with the study was motivated by the widespread adoption of GLP-1-based medicines by the population.
Pesquisa clinic exploits biometric data from Galaxy Watch 8
The clinical research will investigate the feasibility of using continuous biometric data, provided by the Galaxy Watch 8. The device, together with the Samsung Health application, will collect crucial information for the medical monitoring of participants, aiming for a more personalized intervention. Estes essential data includes body composition, physical activity levels and heart rate, offering experts a comprehensive view of patients’ response to drug treatment. The main goal is to provide insights that can lead to more accurate adjustments to the care plan.
In an official statement, the institutions involved explained that the decision to continue with the study was driven by the growing popularity and wide adoption of GLP-1-based medicines. Weight control and the treatment of chronic diseases, such as type 2 diabetes and high blood pressure, are among the reasons that lead people to adopt this type of therapy.
Estrutura of the study and composition of the groups
The study will be conducted under the leadership of Dra. Melissa Putman, director of Centro of Pesquisa in Diabetes of MGH. The analyzes will begin with the recruitment of 100 adults who will begin treatment with weight loss medications, and who will be carefully divided into two distinct groups. The recruitment phase is crucial to ensure a representative base for future analyses.
- The groups will be divided to observe the impact of technological monitoring:
- One of the groups will use the Galaxy Watch as the main monitoring tool, monitoring body composition through bioimpedance. Além will also record physical activities and receive personalized exercise-related guidance.
- The other group will receive guidance and standard care, normally offered to patients starting treatments with medications that stimulate GLP-1 receptors, without the direct assistance of the smartwatch.
Comparing the progress of both groups is essential to determine the effectiveness of the smartwatch as a support tool. The progress of the research and the physiological changes of the volunteers will be assessed using clinical-grade DXA scans, considered the most accurate method for analyzing body composition. Este strict protocol aims to guarantee the validity of the results obtained.
Monitoramento of effects and expected results
The data collected will indicate whether the insights generated by Galaxy Watch 8 can effectively assist patients in developing healthier habits. The analysis will also focus on improving the preservation of muscle mass, a critical aspect of health during GLP-1 treatments. The expectation is that the device can offer practical and measurable support for users.
The Dra. Putman highlighted the strong interest in exploring how continuous data from a wearable device provides valuable insights. Níveis of patient activity, heart rate and body composition are elements that, combined, offer clinicians a more complete view of the impact of treatment. Este monitoring enables faster, data-driven adjustments to the care plan, optimizing individual therapy and improving outcomes for patients.






